Epygenix Therapeutics, Inc.
  • THERAPEUTIC FOCUS
  • OUR TECHNOLOGY
    • PIPELINE
    • OUR SCIENCE
    • CLINICAL TRIALS
  • WHO WE ARE
    • OUR STORY
  • NEWS
  • CONTACT
Select Page

Epygenix Therapeutics to Participate in RW Baird’s Biotech Discovery Series

Jul 21, 2022 | News

Epygenix Therapeutics Receives FDA Orphan Drug Designation for EPX-100 For Treatment of Ohtahara Syndrome

Jun 29, 2022 | News

Epygenix Therapeutics to Provide Update at the Dravet Syndrome Foundation (DSF) 2022 Conference

Jun 9, 2022 | News

First Canadian Participant Dosed in ARGUS Trial, A Phase 2 Potentially Pivotal Study of EPX-100 Treatment of Dravet Syndrome

Jun 1, 2022 | News

Epygenix Therapeutics Announces Appointment of Dr. Lorianne Masuoka as Chief Medical Officer

May 23, 2022 | News

Epygenix Therapeutics To Participate in UBS Healthcare Virtual 1×1 Day

May 20, 2022 | News

« Older Entries

Recent Posts

  • Epygenix Therapeutics to Participate in RW Baird’s Biotech Discovery Series
  • Epygenix Therapeutics Receives FDA Orphan Drug Designation for EPX-100 For Treatment of Ohtahara Syndrome
  • Epygenix Therapeutics to Provide Update at the Dravet Syndrome Foundation (DSF) 2022 Conference
Epygenix

Epygenix Therapeutics, Inc. is developing precision medicine for rare and catastrophic forms of genetic epilepsy, such as Dravet Syndrome, Lennox-Gastaut Syndrome, Infantile Spasm, and Otahara syndrome.

Biotech Web Design Company

©2022 Epygenix Therapeutics, Inc.

How To Find Us

Epygenix Therapeutics, Inc.
140 E. Ridgewood Ave.
Suite 415, South Tower
Paramus, NJ 07652

Phone: 1 (201) 940-7377

Fax: 1 (201) 940-7218

info@epygenix.com

 

   

Latest News

  • Epygenix Therapeutics to Participate in RW Baird’s Biotech Discovery Series
  • Epygenix Therapeutics Receives FDA Orphan Drug Designation for EPX-100 For Treatment of Ohtahara Syndrome
  • Epygenix Therapeutics to Provide Update at the Dravet Syndrome Foundation (DSF) 2022 Conference